Cargando…
Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enro...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366071/ https://www.ncbi.nlm.nih.gov/pubmed/22829974 http://dx.doi.org/10.1038/bcj.2012.18 |
_version_ | 1782234708422164480 |
---|---|
author | Mizuta, S Matsuo, K Maeda, T Yujiri, T Hatta, Y Kimura, Y Ueda, Y Kanamori, H Usui, N Akiyama, H Takada, S Yokota, A Takatsuka, Y Tamaki, S Imai, K Moriuchi, Y Miyazaki, Y Ohtake, S Ohnishi, K Naoe, T |
author_facet | Mizuta, S Matsuo, K Maeda, T Yujiri, T Hatta, Y Kimura, Y Ueda, Y Kanamori, H Usui, N Akiyama, H Takada, S Yokota, A Takatsuka, Y Tamaki, S Imai, K Moriuchi, Y Miyazaki, Y Ohtake, S Ohnishi, K Naoe, T |
author_sort | Mizuta, S |
collection | PubMed |
description | We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted. |
format | Online Article Text |
id | pubmed-3366071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-33660712012-06-04 Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL Mizuta, S Matsuo, K Maeda, T Yujiri, T Hatta, Y Kimura, Y Ueda, Y Kanamori, H Usui, N Akiyama, H Takada, S Yokota, A Takatsuka, Y Tamaki, S Imai, K Moriuchi, Y Miyazaki, Y Ohtake, S Ohnishi, K Naoe, T Blood Cancer J Original Article We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted. Nature Publishing Group 2012-05 2012-05-18 /pmc/articles/PMC3366071/ /pubmed/22829974 http://dx.doi.org/10.1038/bcj.2012.18 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Mizuta, S Matsuo, K Maeda, T Yujiri, T Hatta, Y Kimura, Y Ueda, Y Kanamori, H Usui, N Akiyama, H Takada, S Yokota, A Takatsuka, Y Tamaki, S Imai, K Moriuchi, Y Miyazaki, Y Ohtake, S Ohnishi, K Naoe, T Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title_full | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title_fullStr | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title_full_unstemmed | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title_short | Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
title_sort | prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in bcr–abl-positive all |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366071/ https://www.ncbi.nlm.nih.gov/pubmed/22829974 http://dx.doi.org/10.1038/bcj.2012.18 |
work_keys_str_mv | AT mizutas prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT matsuok prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT maedat prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT yujirit prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT hattay prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT kimuray prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT ueday prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT kanamorih prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT usuin prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT akiyamah prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT takadas prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT yokotaa prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT takatsukay prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT tamakis prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT imaik prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT moriuchiy prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT miyazakiy prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT ohtakes prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT ohnishik prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall AT naoet prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall |